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Abstract
Background: This study aimed to elucidate the influence of skin invasion in patients with recurrent head and neck
cancer treated with re-irradiation using stereotactic radiotherapy.
Materials: We reviewed 104 patients treated using CyberKnife in four institutions.
Results: Nine cases of skin invasion were recognized (8.6 %). Larger tumors tended to exhibit skin invasion. The skin
invasion (+) group showed a lower response rate (0/9, 0 %) than the skin invasion (−) group (56/95, 59 %) (p = 0.002).
The skin invasion (+) group showed lower local control (LC) and progression free survival (PFS) rates, both 0 % at
6 months, than the skin invasion (−) group, which had a LC of 69 % (p = 0.0001) and a PFS of 48 % at 1 year (p = 0.0157).
Median survival time and one-year survival rates for the skin invasion (+) and (−) groups were 6.6 vs. 15.3 months and
14 % vs. 59 % (p = 0.0005), respectively. No patient with skin invasion survived more than 14.4 months. The percentage
of patients who developed grade 3 or higher toxicity was 44 % in the skin invasion (+) group and 18 % in the skin
invasion (−) group (p = 0.14).
Conclusions: Skin invasion is an important predictor of poor prognosis in recurrent head and neck cancer after
re-irradiation with stereotactic radiation therapy.
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Background
Advanced radiotherapy techniques, i.e., stereotactic body
radiation therapy (SBRT), intensity-modulated radiation
therapy (IMRT), image-guided external radiotherapy,
and new chemotherapeutic agents have improved the
outcomes of unresectable head and neck cancer treat-
ments [1, 2]. However, locoregional failure remains a
major obstacle and requires further treatment. Unfortu-
nately, one-third of the patients are eligible for salvage
surgery [3]. Chemotherapy is frequently preferred, yet it
results in less than 9 months of median survival [4].
With the advancements of modern radiation technique,
re-irradiation has become a fascinating optional therapy
using advanced technologies, i.e., IMRT and/or SBRT.
The image-guided stereotactic radiotherapy system,
CyberKnife, enables to deliver precise doses over short
treatment periods [5–9]. Several institutions, including
ours, reported the outcome and toxicity of re-irradiation
using CyberKnife hypofractionated SBRT [5–9]. We
have experienced lethal carotid blowout syndrome
(CBOS) and found that skin invasion is an ominous pre-
dictor of CBOS-related death after CBOS [9]. These
findings prompted us to investigate tumor factors, i.e.,
the presence of ulceration, in the prognosis of head and
neck cancer patients [10]. However, skin invasion is rare;
thus, it was difficult to assess its role simultaneously. We
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examined multi-institutional charts to identify the cases
with skin invasion. The aim of this study was to examine
the role of skin invasion in tumor control and toxicity
after re-irradiation using CyberKnife SBRT for head and
neck cancer patients.
Materials and methods
We retrospectively reviewed medical records of patients
who underwent CyberKnife SBRT (Accuray; Sunnyvale,
CA, USA) at four hospitals (Soseikai General Hospital,
Osaka University Hospital, Fujimoto Hayasuzu Hospital,
and Okayama Kyokuto Hospital) during 2000–2010.
Among 200 head and neck cancer patients who received
reirradiation for residual or recurrent head and neck can-
cer, only those patients who satisfied the following criteria
were included: image evaluation including computed tom-
ography (CT) and/or Magnetic resornance imaging (MRI)
before SBRT (Fig. 1) to confirm the presence or absence of
skin invasion and had completed a course of radical treat-
ment, including radiotherapy at ≥ 40 Gy (EQD2 prescribed
in below), with or without chemotherapy and surgery. A
total of 104 patients were eligible for assessment. The first
course of radiotherapy was delivered by conventional tech-
nique using a linear accelerator. At the time of recurrence
or residual disease, SBRT reirradiation was performed
using the CyberKnife system. Patients received a median
dose of 30 Gy (range, 15–39 Gy) over a median of 5 frac-
tions (range, 3–8 fractions) that were prescribed at D90,
D95, or a marginal dose. D90 (D95) was defined as a mini-
mum dose covering 90 % (95 %) of the planning target vol-
ume (PTV). The marginal dose prescription was defined
by percent (100 %, maximum dose) of the isodose curve
covering the PTV. Median cumulative dose (dose from the
first course of radiation and dose received from the second
course of radiation) was 91Gy (range: 62-146Gy). Interval
between the first course of radiation and the second course
of radiation was 14.5 months in median value (range: 0.7-
1180 months). The presence of skin invasion was identi-
fied by imaging analysis CT and/or MRI such as computed
tomography and/or magnetic resonance imaging (contrast-
enhanced if required). A biologically equivalent dose (BED)
was calculated into equivalent 2-Gy fractions (EQD2) using
the linear quadratic model: EQD2 = prescription dose × (α/
β + dose per fraction)/(α/β + 2), where α/β = 10 for tumors
and 3 for organs at risk. All studies on humans described
in the present manuscript were carried out in accordance
with the Helsinki Declaration. Written informed consent
was obtained from the patients for publication of this data
and the accompanying images.
Statistical analysis
All statistical analyses were performed using Stat-view
5.0 statistical software (SAS Institute, Inc., Cary, NC,
USA). The percentage values were analyzed using the χ2
test, and values were compared using Mann–Whitney U
analysis. Cumulative incidences were estimated by the
Kaplan–Meier method. The durations were calculated
from the first day of CyberKnife SBRT. Cut-off value
was set at average or median value of each variable if
Fig. 1 Presentation of a case associated with skin invasion. An 83 year
old man with diagnosis of carcinoma maxillary sinus (T3N0) underwent
radiotherapy with 66 Gy in 33 fractions associated with intra-arterial
chemotherapy (cisplatin). A recurrent tumor was detected at the
primary site eight months later. He then received 50 Gy in 25 fractions
of re-irradiation; however, he developed another 2nd recurrence six
months later. CyberKnife hypofractionated stereotactic radiation therapy
was performed with 25.04 Gy in 8 fractions. The tumor exhibited skin
invasion with larger PTV (124 cm3). He developed local recurrence with
skin fistula 3 months after treatment and died 10 months later
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otherwise stated. All analysis used a p-value < 0.05 level
of significance.
Results
The median follow-up time for the surviving patients
after SBRT was 13.7 months (range 1–122 months).
There were significant differences in PTV between the
skin invasion (+) and (−) cases (Table 1). In other words,
larger tumors tended to exhibit more skin invasion.
The skin invasion (+) group showed a lower response
rate (0/9, 0 %) than the skin invasion (−) group (56/95,
59 %) (p = 0.002) (Table 2). (Table 2) Notably, no pa-
tient in the skin invasion (+) group obtained complete
or partial remission. The skin invasion (+) group had
both a local control (LC) and a progression-free sur-
vival (PFS) rate of 0 % at 6 months, whereas the skin
Table 1 Comparison of patients characteristics, treatment factors and outcome between skin invasion (+) and (−) patients
Variables Strata Skin invasion (−) Skin invasion (+) p-value
n = 95 n = 9
No. or mean +/− SD, median (range) (%) No. or median (range)
Age 64 (43–88) 61 (56–83) 0.65
Gender Female 26 (27 %) 1 (11 %) 0.5
Male 69 (73 %) 8 (89 %)
Disease Nasopharyngeal cancer 41 (43 %) 0 (0 %) 0.12
Oropharyngeal cancer 19 (20 %) 2 (22 %)
Hypopharyngeal cancer 9 (9 %) 2 (22 %)
Oral cancer 10 (11 %) 2 (22 %)
Nasal/pranasal 16 (17 %) 3 (33 %)
Irradiated area Primary 73 (77 %) 5 (56 %) 0.31
Lymph node 22 (23 %) 4 (44 %)
rT stage T0 12 (13 %) 2 (22 %) 0.25
T1 18 (19 %) 0 (0 %)
T2 9 (9 %) 1 (11 %)
T3 11 (12 %) 3 (33 %)
T4 30 (32 %) 3 (33 %)
NA 15 (16 %) 0 (0 %)
rN stage N0 69 (73 %) 4 (44 %) 0.32
N1 18 (19 %) 3 (33 %)
N2 5 (5 %) 1 (11 %)
N3 1 (1 %) 0 (0 %)
NA 2 (2 %) 1 (11 %)
Ulceration (−) 74 (78 %) 5 (56 %) 0.27
(+) 21 (22 %) 4 (44 %)
Surgical history (−) 55 (58 %) 3 (33 %) 0.28
(+) 40 (42 %) 6 (67 %)
Planning target volume cm3 26.2 (0.9–339) 64.6 (5.2–241) 0.04
Interval months 16.0 (1–1180) 8.3 (5.1–44) 0.1
Dose EQD2 (a/b = 10) 41.9 (18.9–74.7) 34.6 (31.2–57.8) 0.12
Cumulative dose EQD2 (a/b = 10) 117.1 (62–192) 105. 4 (96.6–130) 0.09
Initial tumor response CR + PR 55 (59 %) 0 (0 %) 0
SD + PD 38 (41 %) 9 (100 %)
Toxicity Grade 0–2 78 (82 %) 5 (56 %) 0.14
Grade 3- 17 (18 %) 4 (44 %)
CR complete reponse, PR partial response, NC no change, PD progressive disease
Bold values indicate statistically significance
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invasion (−) group had a LC rate of 69 % (p = 0.0001)
and a PFS rate of 47 % at 1 year (p = 0.0157) (Fig. 2).
Median survival time and one-year survival rates for
the skin invasion (+) and (−) groups were 6 vs.
15.3 months and 16.7 % vs. 57 % (p = 0.0005), respect-
ively (Fig. 2). No patients with skin invasion survived more
than 14.4 months. Therefore, there were statistical
significant differences in all the prognostic indicators (ini-
tial response rate, LC, PFS and overall survival) between
the skin invasion (+) and (−) cases (Fig. 2), indicating poor
prognosis for patients with skin invasion. The local control
rate, progression-free survival rate, and overall survival rate
at 1 year were 58, 31, and 47 %, respectively in the treat-
ment interval ≦30 months group (n = 68) and 76 % (p =
0.11), 70 % (p = 0.002), and 66 % (p = 0.02) in the treat-
ment interval 30 months < group (n = 36).
Toxicity
A total of 21 patients experienced grade 3 or higher
toxicities (20 %). Among them, CBOS occurred in 11
patients and resulted in nine deaths, whereas the other
two patients recovered following intervention. All lethal
toxicities were due to CBOS. CBOS developed in 22 % of
the patients in the skin invasion (+) group (2/9), and in
only 9 % of those in the skin invasion (−) group (9/95)
(p = 0.24). Two cases of CBOS with skin invasion could
not be salvaged and showed poor prognosis (1.6 months
and 13.6 months after reirradiation) resulted in death.
There are no CBOS case in patients with carotid inva-
sion ≦180° (Table 2). In patients with carotid invasion
180°<, 50 % of patients showed CBOS with skin inva-
sion, whereas 19 % without (Table 2). We could not
find statistical significance in prescribed dose between
Fig. 2 Influence of skin invasion. The thick line represents the skin invasion (−) group and the thin line represents the skin invasion (+) group.
a Local control rates according to the presence of skin invasion. b Progression-free survival rates according to the presence of skin invasion.
c Overall survival rates according to the presence of skin invasion
Table 2 CBOS according to carotid invasion and skin invasion
Variables Pt. NO. CBOS ratio
Carotid invasion Skin invasion CBOS
≤180 degree - - 35 0 %
+ 0
+ - 5 0 %
+ 0
180 degree < - - 39 19 %
+ 9
+ - 2 50 %
+ 2
Not available - - 12 0 %
+ 0
+ - 0 0 %
+ 0
CBOS carotid blow-out syndrome
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CBOS (median 87 Gy: range 75–109 Gy) and non-
CBOS group (median 92 Gy: range 66–146 Gy). Other
grade 3 or higher toxicities included two cases of mu-
cositis requiring percutaneous endoscopic gastrostomy,
two cases of lateral lobe necrosis (one grade 4), five fis-
tulas, one bone necrosis, one soft tissue necrosis, one
visual disturbance, and one ulceration. The percentage
of patients who developed grade 3 or higher toxicity
was 44 % in the skin invasion (+) group and 18 % in the
skin invasion (−) group (p = 0.14). Although this differ-
ence was not statistically significant, the skin invasion
(+) group showed three times more frequent severe
toxicity of grade 3 or higher, which implied a vulner-
ability to suffer severe toxicities in the skin invasion (+)
group.
Discussion
This is the first study to examine the role of skin inva-
sion in recurrent head and neck cancer patients who
underwent re-irradiation with CyberKnife SBRT. Skin
invasion is an established risk factor for newly diagnosed
head and neck cancer patients. It is regarded as a T4 cat-
egory in the TNM classification of various types of head
and neck cancers, i.e., oral and nasal/paranasal cancers
[11]. Therefore, it is plausible that skin invasion may be
nasalidentified as a significant predisposing factor after
re-irradiation also. In a previous study, we observed poor
prognosis in post-operative patients with skin invasion
in case of CBOS after SBRT [7] (Fig. 1). This observation
prompted us to explore the role of skin invasion in re-
irradiation. As highfound that skin invasion is a
predictor of poor prognosis after re-irradiation, and no
patients with skin invasion survived more than
14.4 months after SBRT. None of the patients with skin
invasion obtained a partial response or a better clinical
outcome after SBRT, and all cases recurred within
6 months. The poor tumor response and local control
could be important findings to explain the poor survival
rate in these patients.
We did not find a statistically significant correlation
between skin invasion and CBOS nor toxicities. It can
be predicted that skin invasion itself does not always
imply tumor invasion into the carotid artery. For ex-
ample, it is rare to find carotid invasion in nasal or para-
nasal cancer patients with skin invasion (Fig. 1). On the
other hand, as there is a close relationship between skin
invasion and tumor volume, larger tumors tend to show
skin invasion and, at the same time, may pose higher
risk of serious toxicities. In general, the risk of higher
toxicity should be particularly considered when evaluat-
ing the indications for re-irradiation. Our data of 44 %
of patients with grade ≥ 3 toxicity in the skin invasion
(+) group could be high enough to prompt to consider
more strict eligibility criteria for re-irradiation in patients
with skin invasion. Several attempts have been made to re-
duce toxicity. Instead of daily SBRT, treatment on alter-
nate days could be an option [5-12]. Conventional dose
fractionation (1.8 − 2 Gy/fraction) also could reduce tox-
icity. IMRT is now being explored [13]; however, there is
little data in cases with skin invasion. In addition, even
IMRT caused a cumulative incidence of late grade ≥ 3 tox-
icity of 23, 27, and 66 % at 1, 2, and 5 years, respectively.
In 4 patients, death was attributed toxicity including fatal
bleeding (n = 2), aspiration pneumonia (n = 1), and
skin necrosis (n = 1). Therefore, risk factor assessment
including tumor factors, i.e., ulceration and skin invasion,
should be included in evaluating patient eligibility for re-
irradiation.
This study had several limitations. First, because of the
small number of patients with skin invasion, it is difficult
to state clearly the role of this factor without confound-
ing variables. In our analysis, skin invasion was related
to tumor size, which indicates tumor aggressiveness. In
addition, this study was a retrospective analysis that in-
cluded a small number of patients with a short follow-
up period, thus selection- and physician-based biases
may exist. Therefore, these results should be confirmed
in a prospective trial with a larger number of patients
and longer follow-up period.
In conclusion, skin invasion is an important predictive
factor for the prognosis of recurrent head and neck can-
cer after SBRT.
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